130 related articles for article (PubMed ID: 20963355)
41. Significance of trisomy 7 related to PCNA index in cholesteatoma.
Lavezzi A; Mantovani M; Cazzulo A; Turconi P; Matturri L
Am J Otolaryngol; 1998; 19(2):109-12. PubMed ID: 9550442
[TBL] [Abstract][Full Text] [Related]
42. Immunohistochemical analysis of the cytokeratin expression in middle ear cholesteatoma and related epithelial tissues.
Broekaert D; Coucke P; Leperque S; Ramaekers F; Van Muijen G; Boedts D; Leigh I; Lane B
Ann Otol Rhinol Laryngol; 1992 Nov; 101(11):931-8. PubMed ID: 1280020
[TBL] [Abstract][Full Text] [Related]
43. Reversibility of experimental cholesteatoma epithelium using Mongolian gerbils.
Park K; Choung YH; Chun YM; Lee JS; Hong SP
Acta Otolaryngol; 2005 May; 125(5):540-6. PubMed ID: 16092548
[TBL] [Abstract][Full Text] [Related]
44. Antigen expression of epithelial markers, collagen IV and Ki67 in middle ear cholesteatoma. An immunohistochemical Study.
Ergün S; Zheng X; Carlsöö B
Acta Otolaryngol; 1994 May; 114(3):295-302. PubMed ID: 7521107
[TBL] [Abstract][Full Text] [Related]
45. p53 Expression and keratinocyte hyperproliferation in middle ear cholesteatoma.
Motamed M; Powe D; Kendall C; Birchall JP; Banerjee AR
Clin Otolaryngol Allied Sci; 2002 Dec; 27(6):505-8. PubMed ID: 12472520
[TBL] [Abstract][Full Text] [Related]
46. [A study on the state of cell proliferation and apoptosis in human middle ear cholesteatoma].
Yu Q; Jin K
Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2001 Oct; 15(10):450-1. PubMed ID: 12541689
[TBL] [Abstract][Full Text] [Related]
47. Up-regulation of peroxidase proliferator-activated receptor gamma in cholesteatoma.
Hwang SJ; Kang HJ; Song JJ; Kang JS; Woo JS; Chae SW; Lee HM
Laryngoscope; 2006 Jan; 116(1):58-61. PubMed ID: 16481810
[TBL] [Abstract][Full Text] [Related]
48. Expression of transforming growth factor-alpha (TGF-alpha) in cholesteatoma.
Shiwa M; Kojima H; Moriyama H
J Laryngol Otol; 1998 Aug; 112(8):750-4. PubMed ID: 9850316
[TBL] [Abstract][Full Text] [Related]
49. Expression patterns of cytokeratins in cholesteatomas: evidence of increased migration and proliferation.
Kim HJ; Tinling SP; Chole RA
J Korean Med Sci; 2002 Jun; 17(3):381-8. PubMed ID: 12068144
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical characterization of the epidermoid formation in the middle ear.
Liang J; Michaels L; Wright A
Laryngoscope; 2003 Jun; 113(6):1007-14. PubMed ID: 12782813
[TBL] [Abstract][Full Text] [Related]
51. [Study of long non-coding RNA HOTAIR expression in middle ear cholesteatoma].
Li Q; Wang HQ; Chen YQ; Xiong S; Zeng L
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Feb; 31(4):250-253. PubMed ID: 29871236
[No Abstract] [Full Text] [Related]
52. Canal wall down tympanoplasty with canal reconstruction for middle-ear cholesteatoma: post-operative hearing, cholesteatoma recurrence, and status of re-aeration of reconstructed middle-ear cavity.
Ikeda M; Yoshida S; Ikui A; Shigihara S
J Laryngol Otol; 2003 Apr; 117(4):249-55. PubMed ID: 12816211
[TBL] [Abstract][Full Text] [Related]
53. The role of inhibitor of DNA-binding (Id1) in hyperproliferation of keratinocytes: the pathological basis for middle ear cholesteatoma from chronic otitis media.
Hamajima Y; Komori M; Preciado DA; Choo DI; Moribe K; Murakami S; Ondrey FG; Lin J
Cell Prolif; 2010 Oct; 43(5):457-63. PubMed ID: 20887552
[TBL] [Abstract][Full Text] [Related]
54. The role of S100A1 in external auditory canal cholesteatoma.
Naim R; Hormann K
Oncol Rep; 2006 Oct; 16(4):671-5. PubMed ID: 16969478
[TBL] [Abstract][Full Text] [Related]
55. Cell cycle inhibitory protein p27 in human middle ear cholesteatoma.
Kuczkowski J; Bakowska A; Pawelczyk T; Narozny W; Mikaszewski B
ORL J Otorhinolaryngol Relat Spec; 2006; 68(5):296-301. PubMed ID: 16825801
[TBL] [Abstract][Full Text] [Related]
56. Immunohistochemical analysis of retraction pocket pars tensa of tympanic membrane in children.
Urík M; Hurník P; Žiak D; Machač J; Šlapák I; Motyka O; Jabandžiev P
Int J Pediatr Otorhinolaryngol; 2019 Jul; 122():111-116. PubMed ID: 30999159
[TBL] [Abstract][Full Text] [Related]
57. Method for removal of samples of ear canal and tympanic membrane for histologic and immunhistochemical study.
Gurgel JD; Pereira CS; Fregnani JH; Ribeiro Fde A
Braz J Otorhinolaryngol; 2012 Feb; 78(1):37-42. PubMed ID: 22392236
[TBL] [Abstract][Full Text] [Related]
58. Kinetic analysis of cell proliferation using bromodeoxyuridine labeling and in situ detection of dying cells in the tympanic membrane and middle ear cholesteatoma.
Koba R; Yagi M; Tabe H; Kawabata I
Arch Histol Cytol; 1996 Oct; 59(4):339-46. PubMed ID: 8937634
[TBL] [Abstract][Full Text] [Related]
59. Role of Langerhans cells, Ki-67 protein and apoptosis in acquired cholesteatoma: prospective clinical study.
Akdogan V; Yilmaz I; Canpolat T; Ozluoglu LN
J Laryngol Otol; 2013 Mar; 127(3):252-9. PubMed ID: 23331470
[TBL] [Abstract][Full Text] [Related]
60. The nature of the epithelium in acquired cholesteatoma.
Lee RJ; Mackenzie IC; Hall BK; Gantz BJ
Clin Otolaryngol Allied Sci; 1991 Apr; 16(2):168-73. PubMed ID: 1712679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
